Your browser doesn't support javascript.
loading
Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma.
Nishimura, Tadashi; Fujiwara, Takumi; Fujimoto, Hajime; Tarumi, Hirotoshi; Tsuji, Chikashi; Iwanaka, Soichi; Sakakura, Yasumasa; Naito, Masahiro; Okugawa, Yoshinaga; Yasuma, Taro; Gabazza, Esteban Cesar; Oomoto, Yasuhiro; Kobayashi, Tetsu; Ibata, Hidenori.
Afiliación
  • Nishimura T; Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu, Japan.
  • Fujiwara T; Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.
  • Fujimoto H; Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.
  • Tarumi H; Department of Genomic Medicine, Mie University Hospital, Tsu, Japan.
  • Tsuji C; Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.
  • Iwanaka S; Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu, Japan.
  • Sakakura Y; Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu, Japan.
  • Naito M; Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu, Japan.
  • Okugawa Y; Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu, Japan.
  • Yasuma T; Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu, Japan.
  • Gabazza EC; Department of Genomic Medicine, Mie University Hospital, Tsu, Japan.
  • Oomoto Y; Department of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.
  • Kobayashi T; Department of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu, Japan.
  • Ibata H; Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu, Japan.
Thorac Cancer ; 14(7): 709-713, 2023 03.
Article en En | MEDLINE | ID: mdl-36710365
Epidermal growth factor receptor (EGFR)-mutated squamous cell carcinoma (SCC) is less common than adenocarcinoma. The third-generation EGFR-tyrosine kinase inhibitor, osimertinib, is effective in EGFR-mutated lung adenocarcinoma, but its efficacy in EGFR-mutated lung SCC is unclear. The patient was an 83-year-old male. He was diagnosed with SCC of the lung, and molecular analysis revealed that the tumor was positive for EGFR exon19 deletion. He was treated with osimertinib 80 mg/day. No adverse events were observed, but after 18 days of therapy, he complained of dyspnea, and a computed tomography scan showed enlarged lung cancer. The case was categorized as a progressive disease. The patient died 3 weeks later. The autopsy findings confirmed the diagnosis of lung SCC, with morphology and immunohistochemical staining identical to the tumor obtained by bronchoscopy. Next-generation sequencing showed the presence of TP53 R158L, CDK6, and KRAS amplifications. The current case report shows that next-generation sequencing can explain why osimertinib is ineffective in EGFR-mutated SCC.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Diagnostic_studies Límite: Aged80 / Humans / Male Idioma: En Revista: Thorac Cancer Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Singapur
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Diagnostic_studies Límite: Aged80 / Humans / Male Idioma: En Revista: Thorac Cancer Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Singapur